A novel senotherapeutic strategy with azithromycin for preventing endometriosis progression
Abstract Background Endometriosis is an estrogen-dependent chronic inflammatory disease, however the mechanisms underlying inflammation remain unclear. Non-hormonal drugs that can prevent endometriosis progression and resolve endometriotic infertility are urgently required. We thus focused on cellul...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-03-01
|
| Series: | Reproductive Biology and Endocrinology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12958-025-01381-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849391023338291200 |
|---|---|
| author | Reina Sonehara Tomoko Nakamura Takehiko Takeda Satoshi Kaseki Tomomi Seki Hideaki Tanaka Atsushi Yabuki Natsuki Miyake Ayako Muraoka Satoko Osuka Akira Iwase Hiroaki Kajiyama |
| author_facet | Reina Sonehara Tomoko Nakamura Takehiko Takeda Satoshi Kaseki Tomomi Seki Hideaki Tanaka Atsushi Yabuki Natsuki Miyake Ayako Muraoka Satoko Osuka Akira Iwase Hiroaki Kajiyama |
| author_sort | Reina Sonehara |
| collection | DOAJ |
| description | Abstract Background Endometriosis is an estrogen-dependent chronic inflammatory disease, however the mechanisms underlying inflammation remain unclear. Non-hormonal drugs that can prevent endometriosis progression and resolve endometriotic infertility are urgently required. We thus focused on cellular senescence as a novel feature of endometriosis. Senescent cells cause chronic inflammation via the senescence-associated secretory phenotype (SASP) factor. It has been reported the effects of senolysis for various diseases in recent years. The aim of this study was to validate the involvement of cellular senescence in endometriosis and as the effects of senolytic drug to develop a novel non-hormonal therapeutic strategy for endometriosis. Methods The senescence markers were assessed by morphological features and semiquantitative immunofluorescence staining (senescence-associated b-galactosidase [SA-b-Gal], the cyclin-dependent kinase inhibitor 2 A locus [p16INK4a], and laminB1) to compare among cell types (normal endometrial stromal cells [nESCs], endometrial stromal cells with endometriosis [eESCs], and ovarian endometriosis [OE] cyst-derived stromal cells [CSCs]). Expression of SASP markers was examined in cell culture supernatants using a cytokine array. In addition, the effects of senolytic drugs (azithromycin [AZM] and navitoclax [ABT263]) on endometriosis were evaluated in vitro and in vivo. The in vivo study used the endometriosis mice model. Results CSCs exhibited stronger senescence markers. Semi-quantitative SA-β-Gal and p16INK4a staining intensities were significantly increased, and that of LaminB1 was decreased in CSCs compared to those in nESCs and eESCs (SA-b-Gal, P < 0.001; p16INK4a, P < 0.05; LaminB1, P < 0.05). Cytokine array analysis revealed elevated SASP-related cytokine levels, including interleukin-6 (IL-6), in CSC supernatants compared to those in nESCs. AZM and ABT263 reduced the viable fraction in CSCs (AZM: P < 0.001, ABT263: P < 0.01). Furthermore, AZM suppressed IL-6 expression in CSC culture supernatants (P < 0.05). In murine model, AZM administration reduced endometriotic lesion volume compared to that in vehicle (P < 0.05). Proliferative activity, IL-6 expression levels, and fibrosis within endometriotic lesions also decreased (Ki67, P < 0.01; IL-6, P < 0.001; fibrosis, P < 0.001). Conclusions Our findings show that cellular senescence is involved in the pathogenesis of endometriosis and that AZM may be useful for preventing endometriosis progression by suppressing the secretion of IL-6 as a SASP. |
| format | Article |
| id | doaj-art-5e5ac3cc98fb4aa3b30e9cb85c38c4e8 |
| institution | Kabale University |
| issn | 1477-7827 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | BMC |
| record_format | Article |
| series | Reproductive Biology and Endocrinology |
| spelling | doaj-art-5e5ac3cc98fb4aa3b30e9cb85c38c4e82025-08-20T03:41:14ZengBMCReproductive Biology and Endocrinology1477-78272025-03-0123111110.1186/s12958-025-01381-4A novel senotherapeutic strategy with azithromycin for preventing endometriosis progressionReina Sonehara0Tomoko Nakamura1Takehiko Takeda2Satoshi Kaseki3Tomomi Seki4Hideaki Tanaka5Atsushi Yabuki6Natsuki Miyake7Ayako Muraoka8Satoko Osuka9Akira Iwase10Hiroaki Kajiyama11Department of Obstetrics and Gynecology, Nagoya University Graduate School of MedicineDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of MedicineDepartment of Maternal and Perinatal Medicine, Nagoya University HospitalDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of MedicineDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of MedicineDepartment of Maternal and Perinatal Medicine, Nagoya University HospitalDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of MedicineDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of MedicineDepartment of Maternal and Perinatal Medicine, Nagoya University HospitalDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of MedicineDepartment of Obstetrics and Gynecology, Gunma University Graduate School of MedicineDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of MedicineAbstract Background Endometriosis is an estrogen-dependent chronic inflammatory disease, however the mechanisms underlying inflammation remain unclear. Non-hormonal drugs that can prevent endometriosis progression and resolve endometriotic infertility are urgently required. We thus focused on cellular senescence as a novel feature of endometriosis. Senescent cells cause chronic inflammation via the senescence-associated secretory phenotype (SASP) factor. It has been reported the effects of senolysis for various diseases in recent years. The aim of this study was to validate the involvement of cellular senescence in endometriosis and as the effects of senolytic drug to develop a novel non-hormonal therapeutic strategy for endometriosis. Methods The senescence markers were assessed by morphological features and semiquantitative immunofluorescence staining (senescence-associated b-galactosidase [SA-b-Gal], the cyclin-dependent kinase inhibitor 2 A locus [p16INK4a], and laminB1) to compare among cell types (normal endometrial stromal cells [nESCs], endometrial stromal cells with endometriosis [eESCs], and ovarian endometriosis [OE] cyst-derived stromal cells [CSCs]). Expression of SASP markers was examined in cell culture supernatants using a cytokine array. In addition, the effects of senolytic drugs (azithromycin [AZM] and navitoclax [ABT263]) on endometriosis were evaluated in vitro and in vivo. The in vivo study used the endometriosis mice model. Results CSCs exhibited stronger senescence markers. Semi-quantitative SA-β-Gal and p16INK4a staining intensities were significantly increased, and that of LaminB1 was decreased in CSCs compared to those in nESCs and eESCs (SA-b-Gal, P < 0.001; p16INK4a, P < 0.05; LaminB1, P < 0.05). Cytokine array analysis revealed elevated SASP-related cytokine levels, including interleukin-6 (IL-6), in CSC supernatants compared to those in nESCs. AZM and ABT263 reduced the viable fraction in CSCs (AZM: P < 0.001, ABT263: P < 0.01). Furthermore, AZM suppressed IL-6 expression in CSC culture supernatants (P < 0.05). In murine model, AZM administration reduced endometriotic lesion volume compared to that in vehicle (P < 0.05). Proliferative activity, IL-6 expression levels, and fibrosis within endometriotic lesions also decreased (Ki67, P < 0.01; IL-6, P < 0.001; fibrosis, P < 0.001). Conclusions Our findings show that cellular senescence is involved in the pathogenesis of endometriosis and that AZM may be useful for preventing endometriosis progression by suppressing the secretion of IL-6 as a SASP.https://doi.org/10.1186/s12958-025-01381-4EndometriosisCellular senescenceSASPIL-6SenotherapyAzithromycin |
| spellingShingle | Reina Sonehara Tomoko Nakamura Takehiko Takeda Satoshi Kaseki Tomomi Seki Hideaki Tanaka Atsushi Yabuki Natsuki Miyake Ayako Muraoka Satoko Osuka Akira Iwase Hiroaki Kajiyama A novel senotherapeutic strategy with azithromycin for preventing endometriosis progression Reproductive Biology and Endocrinology Endometriosis Cellular senescence SASP IL-6 Senotherapy Azithromycin |
| title | A novel senotherapeutic strategy with azithromycin for preventing endometriosis progression |
| title_full | A novel senotherapeutic strategy with azithromycin for preventing endometriosis progression |
| title_fullStr | A novel senotherapeutic strategy with azithromycin for preventing endometriosis progression |
| title_full_unstemmed | A novel senotherapeutic strategy with azithromycin for preventing endometriosis progression |
| title_short | A novel senotherapeutic strategy with azithromycin for preventing endometriosis progression |
| title_sort | novel senotherapeutic strategy with azithromycin for preventing endometriosis progression |
| topic | Endometriosis Cellular senescence SASP IL-6 Senotherapy Azithromycin |
| url | https://doi.org/10.1186/s12958-025-01381-4 |
| work_keys_str_mv | AT reinasonehara anovelsenotherapeuticstrategywithazithromycinforpreventingendometriosisprogression AT tomokonakamura anovelsenotherapeuticstrategywithazithromycinforpreventingendometriosisprogression AT takehikotakeda anovelsenotherapeuticstrategywithazithromycinforpreventingendometriosisprogression AT satoshikaseki anovelsenotherapeuticstrategywithazithromycinforpreventingendometriosisprogression AT tomomiseki anovelsenotherapeuticstrategywithazithromycinforpreventingendometriosisprogression AT hideakitanaka anovelsenotherapeuticstrategywithazithromycinforpreventingendometriosisprogression AT atsushiyabuki anovelsenotherapeuticstrategywithazithromycinforpreventingendometriosisprogression AT natsukimiyake anovelsenotherapeuticstrategywithazithromycinforpreventingendometriosisprogression AT ayakomuraoka anovelsenotherapeuticstrategywithazithromycinforpreventingendometriosisprogression AT satokoosuka anovelsenotherapeuticstrategywithazithromycinforpreventingendometriosisprogression AT akiraiwase anovelsenotherapeuticstrategywithazithromycinforpreventingendometriosisprogression AT hiroakikajiyama anovelsenotherapeuticstrategywithazithromycinforpreventingendometriosisprogression AT reinasonehara novelsenotherapeuticstrategywithazithromycinforpreventingendometriosisprogression AT tomokonakamura novelsenotherapeuticstrategywithazithromycinforpreventingendometriosisprogression AT takehikotakeda novelsenotherapeuticstrategywithazithromycinforpreventingendometriosisprogression AT satoshikaseki novelsenotherapeuticstrategywithazithromycinforpreventingendometriosisprogression AT tomomiseki novelsenotherapeuticstrategywithazithromycinforpreventingendometriosisprogression AT hideakitanaka novelsenotherapeuticstrategywithazithromycinforpreventingendometriosisprogression AT atsushiyabuki novelsenotherapeuticstrategywithazithromycinforpreventingendometriosisprogression AT natsukimiyake novelsenotherapeuticstrategywithazithromycinforpreventingendometriosisprogression AT ayakomuraoka novelsenotherapeuticstrategywithazithromycinforpreventingendometriosisprogression AT satokoosuka novelsenotherapeuticstrategywithazithromycinforpreventingendometriosisprogression AT akiraiwase novelsenotherapeuticstrategywithazithromycinforpreventingendometriosisprogression AT hiroakikajiyama novelsenotherapeuticstrategywithazithromycinforpreventingendometriosisprogression |